Objectives. In-hospital peripheral vascular complications of balloon angioplasty were compared with those of directional atherectomy in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT.I) to identify patients at risk and evaluate costs and outcomes.
peripheral vascular complication rates among patients randomized to angioplasty or atherectomy. Greater age, female gender, postprocedural heparin and intraaortic balloon counterpulsation were predictive of increased risk. In a representative 60% subset, mean hospital costs increased from $9,583 in patients without to $18,350 in those with peripheral vascular complications (p = 0.0001). The unadjusted mortality rate at 1 year was 7.5% for patients with peripheral vascular complications compared with 1.1% for all others (p = 0.0001). These complications identified patients at greater risk of death, myocardial infarction or repeat revascularization at 30 days and 1 year. The atherectomy group had a trend toward more frequent deaths and myocardial infarction.
Conclusions. Directional atherectomy and balloon angioplasty had similar in-hospital peripheral vascular complication rates. Female gender, greater age, postprocedurai heparin and intraaortic balloon counterpulsation were predictive of higher risk. The twofold increase in cost and sevenfold increase in long-term deaths highlight the need to prevent these periprocedural events and monitor patients closely.
(J Am CoU Cardio11995; 26:922-30) Peripheral vascular complications have been reported from the earliest days of percutaneous cardiac catheterization and have been estimated to occur in 0.7% to 9% of patients in observational analyses (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . They include access-site hematomas (with or without extension), thromboembolic occlusions, pseudoaneurysms, arteriovenous fistulas, infection and neurapraxia. The consequences of such complications include blood loss requiring volume, vasopressor or transfusion support (15, 16) ; vascular surgery (with attendant morbidity and mortality) (17) ; longer hospital stays with greater nursing requirements; and higher in-hospital and long-term rehabilitation costs (14) . There are also potential medicolegal ramifications (18) .
Directional coronary atherectomy was approved in 1990 by the Food and Drug Administration as an alternative to percutaneous transluminal coronary (balloon) angioplasty for relieving coronary atherosclerotic obstructions. It typically requires larger (10F to llF) arterial sheaths than balloon angioplasty (-<8F) and takes longer to perform (19) (20) (21) . Rather than simple dilation as in coronary angioplasty, directional coronary atherectomy is based on the principles of cutting, collecting and removing plaque from the affected coronary artery. Although directional coronary atherectomy is the second most widely practiced form of coronary intervention after balloon angioplasty in the United States, there are no randomized trial data in the published reports directly comparing their vascular complication profiles.
The randomized Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) tested the hypothesis that atherectomy is superior to balloon angioplasty (21) . Atherectomy generally resulted in a larger initial target lumen size and a lower rate of angiographic restenosis at 6 months. However, these angiographic outcomes were achieved at the expense of more frequent coronary ischemic complications and higher in-hospital costs. Furthermore, no net clinical advantage (including the need for repeat revascularization) was discernible at 6 months (21) or at 1-year follow-up (22) .
Although peripheral vascular complications were not a specified primary outcome measure, data were prospectively collected. The purpose of the present report is to characterize peripheral vascular complications in CAVEAT-I on the basis of baseline characteristics, treatment assignment and periprocedurai factors. We evaluated hospital costs as well as the independent impact of these events on 30-day and 1-year clinical outcomes (death, myocardial infarction and repeat revascularization).
Methods
CAVEAT-I. The design, methods, enrollment statistics and major findings of CAVEAT-I have been published in detail previously (21) . Briefly, 1,012 patients with clinically significant coronary artery disease deemed suitable for percutaneous intervention using either ->3.0-ram balloon angioplasty or ---6F atherectomy catheter (Atherocath) were enrolled at 35 sites in the United States and Europe. Enrollment began on August 15, 1991 and was completed on April 30, 1992. Angioplasty and atherectomy were performed according to standard techniques (19, 20) . All principal investigators had to have performed at least 50 directional atherectomies and >400 balloon angioplasties to qualify for participation.
All patients received aspirin, and heparin was administered in a bolus of 10,000 U with additional doses to maintain the activated clotting time >350 s during the procedure. Femoral access sheaths were removed from 4 to 24 h after the procedure on the basis of standardized protocols at each randomization site.
End points. The primary end point of CAVEAT-I was angiographic restenosis at 6 months after an initially successful procedure (<50% residual stenosis ascertained by a central angiographic core laboratory). An early clinical end point was prospectively defined as the composite of death, emergency coronary artery bypass surgery, acute myocardial infarction and abrupt vessel closure during the index hospital period. The 6-month clinical end point, prospectively defined as the cumulative composite of death, myocardial infarction, bypass surgery or need for subsequent coronary intervention, was subsequently extended to 1-year follow-up. An economic and quality of life substudy was performed on a prospective basis with 606 patients at 19 of the 32 U.S. study sites. As described previously (21) , all hospital bills covering the period from enrollment through the 6-month follow-up were collected prospectively for these patients. Hospital charges were converted to costs using the revenue center-specific cost/charge ratios and per diems from each hospital's Medicare cost report.
Study data. All data were prospectively recorded at study sites on case report forms that were then submitted to the Duke University coordinating center. After double data entry, range and consistency checks were performed. All case report forms were compared with procedure reports and discharge summaries. A random 15% sample of all forms was audited against complete source medical records.
Statistical analysis. Peripheral vascular complications were defined for the purpose of this study as the composite of pulse loss, pseudoaneurysm, hematoma >4 cm in diameter or groin hemorrhage necessitating blood transfusion. Categoric data are presented as percent of patients and continuous data as medians (25th, 75th percentiles). On the basis of a review of published reports, a set of baseline clinical characteristics (age, gender, height, weight, diabetes, hypertension, history of peripheral vascular disease and current smoking) and periprocedural characteristics (procedure duration, sheath duration, total number of catheterizations, use of coumadin, adjunctive thrombolytic therapy, use of an intraaortic balloon pump, use of heparin and maximal activated clotting time) were prespecifled along with randomization assignment for evaluation of their abilities to predict vascular complications. Univariable analyses of these variables were performed using logistic regression. To avoid using variables (e.g., repeat catheterization) that occurred after a preceding vascular complication to predict a vascular complication, postprocedural variables for patients with a vascular complication were truncated so that any occurring after a vascular complication were discounted. This method created a differential time window of opportunity for occurrence of variables between patients with and without a vascular complication. Therefore, periprocedural variables were truncated for all patients at 18.58 h (the average time to vascular complication occurrence after the start of the procedure), and analyses were repeated. Results were consistent.
Multivariable logistic regression models were developed to evaluate the joint effect of the specified predictors on vascular complications as well as the differential effect of randomized treatment assignment with these predictors (23) . Separate models were developed for clinical and periprocedural factors. In each, a global test of the interactions of treatment with the other main effects was performed. Because there was no evidence of significant differential treatment effects, only models of the main effects were created using stepwise and backward techniques. The exact replication of results using either selection technique provided some insurance about the stability of the final model. The clinical and periprocedural models were then combined to create a final model for the prediction of vascular complications.
Short-(30 day) and long-term (1 year) models were established to reflect the complete clinical consequence of any Early-phase composite end point Use of opposite technique 17.6 Use of perfuskm balloon 14.7 Stent or laser use
2.9
Use of any other device 29.4 Final % stenosis Visually assessed Quantitatively assessed Minimal lumen diameter ( Sheath size and site were not specifically recorded for each patient, but directional coronary atherectomy use implies larger sheath sizes, and use of femoral access sites was universal.
A total of 67 (6.6%) of 1,012 patients had a peripheral vascular complication, of whom 15 (22.4%) had a blood transfusion, 14 (20.9%) underwent vascular surgery, and 2 (3.0%) died. Pulse loss (defined as the absence of previously palpable distal pulses) occurred in 11.9%, and pseudoaneurysms in 10.4% of these patients. Over 85% of patients had a hematoma >4 cm in diameter (Fig. 1) . The unadjusted 1-year mortality rates were 7.5% for patients with a vascular complication and 1.1% for others (p = 0.0001). Patients undergoing directional coronary atherectomy and those undergoing coronary angioplasty bad a vascular complication rate of 6.6% (intention to treat comparison, p = 0.98).
Among patients with peripheral vascular complications, >80% had a hematoma >4 cm in diameter (Fig. 1) . Univariable baseline clinical variables that were significantly predictive of complications (p < 0.05) were female gender, older age, lower body surface area, shorter height and lower weight. The only procedural covariate found predictive of increased risk on univariable analysis (Tables 4 and 5 ) was postprocedural heparin. In general, the use of mechanical support devices was uncommon. Intraaortic balloon counterpulsation showed a nonsignificant univariate association with vascular complications (p = 0.075). Although there was a trend toward a longer median time to sheath removal among patients with a vascular complication, this was not statistically significant (14.83 vs. 10.75 h, p = 0.286).
In a multivariable logistic model combining baseline attributes and procedural covariates, postprocedural heparin, intraaortic balloon counterpulsation, female gender and age were found to be independently predictive of complications (Table 6) . From an overall perspective, every increase in age of 1 year increased the risk of a peripheral vascular complication by 3%. However, patients >65 years old had twice the vascular complication rate of younger patients (9.6% vs. 5.05%, multivariate association, p = 0.03). Among women, the vascular complication rate was 10.8% compared with 5.8% for men (p = 0.003). Diabetes was associated with a lower incidence of vascular complications, and previous peripheral vascular disease was not a significant predictor. No interactions were found between randomization assignment and either baseline variables or procedural covariates. Patients in the economics and quality of life substudy were similar to those not included in the substudy (Table 7) . Mean hospital costs and lengths of stay for the 606 patients in economics and quality of life substudy are shown in Table 8 (categorized by peripheral vascular complications). The occurrence of such complications was an independent predictor of increased costs (p = 0.0001).
Consequences. Among all patients in the study, irrespective of vascular complication, excluding those who underwent bypass surgery, the median decrease in hematocrit among patients randomized to directional coronary atherectomy was 3.8% (1. Two deaths occurred among patients with in-hospital vascular complications (3.0%) compared with no deaths in the rest of the study group. In one patient, multiple transfusions were required for groin bleeding after thrombolysis, whereas another required bilateral above-knee amputation for limb ischemia. At 1 year, the cumulative death rate among these patients had risen to 7.5% compared with 1.1% among patients free of such a complication (p = 0.0001). Moreover, patients who had a vascular complication made up 50% of all those who died at 1 year. Table 9 summarizes the clinical profiles of patients with vascular complications who died during 1 year. Table 10 illustrates the independent effect of vascular complications on clinical outcomes at 30 days and 1 year. The occurrence of in-hospital vascular complications identified a group of patients with a higher long-term likelihood of death, myocardial infarction or repeat revascularization. Patients with a previous myocardial infarction who had a peripheral vascular complication had a nonsignificant trend toward higher composite event rates.
Discussion
The present study. In the CAVEAT-I experience, despite differences in sheath size and procedure time, directional atherectomy and balloon angioplasty had similar overall rates of peripheral vascular complications (6.6%) and vascular sur- gery (2.1%). These complications were associated with twicehigher hospital costs. Trends toward greater requirements for blood transfusions and a higher incidence of pulse loss among patients randomized to directional coronary atherectomy were balanced by the higher incidence of pseudoaneurysm among patients randomized to coronary angioplasty. However, the finding that patients randomized to directional coronary atherectomy had a pattern of higher overall transfusion rates, groin hemorrhage requiring transfusion, peripheral pulse loss and coronary ischemic events raises concern. The data suggest that serious long-term complications (death or myocardial infarction) were more likely among patients with a vascular complication if they had initially been randomized to directional coronary atherectomy. Neither of the two patients randomized to coronary angioplasty who died in hospital underwent directional coronary atherectomy; however, they did cross over to other treatments. Women and older patients were at greatest risk for complications, and postprocedural heparin and use of intraaortic balloon counterpulsation were independent procedural factors linked to complications. There was a nonsignificant trend toward greater interaction between age and vascular complications among patients randomized to coronary angioplasty (but not directional coronary atherectomy), and smoking showed a trend toward greater interaction with directional coronary atherectomy (but not coronary angioplasty). Surprisingly, diabetic patients were at lower risk. Indeed, there were no differences in pulse loss or groin hemorrhage rates for diabetic patients, indicating that both thrombotic and hemorrhagic events were similarly less frequent in this group. Perhaps most intriguing was the significance of these complications as an independent marker for adverse long-term outcomes. Femoral artery thrombus surgically removed; recurrent acute hypotension, heart block during follow-up; tamponade secondary to right ventricular perforation by temporary pacing wire *Adapted from Ellion et al. (22) . #Peripheral vascular complication detected after initial discharge. ARDS -adult respiratory distress syndrome; CAD = coronary artery disease; F = female; LAD -left anterior descending coronary artery; LCx -left circumflex coronary, artery; M -male; MI = myocardial infarction: VF = ventricular fibrillation; VT = ventricular tachycardia; other abbreviations as in Tables 2 to 4 . Previous studies. Several observational studies (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) have attempted to define the relative incidence, predictors and implications of peripheral vascular complications. With the introduction of new devices for coronary revascularization, these complications have become important outcome measures. CAVEAT-I was the first randomized coronary device trial conducted and thus presented a unique opportunity to compare these complications after directional coronary atherectomy and coronary angioplasty.
The observed incidence of peripheral vascular complications in CAVEAT-I was at the higher end of the range of reported rates (Table 11 ). The wide range probably reflects differences in definitions, study populations and accuracy of documentation. In CAVEAT-I, all case report forms were audited against catheterization, procedure and discharge reports. A 15% random sample was audited against all medical records. Double data entry was performed, and all variables used in subsequent reports and presentations underwent computerized data checks. The monitoring committee has consistently been satisfied with the quality of data collection, verification and entry. Because ours is the only detailed report with independent monitoring of the data, it is conceivable that the prevalence of these complications may be underappreciated in practice. Risk factors. The finding that women and older patients had higher baseline risk confirms the observations of others. Some (but not all) studies (7, 11) have also pointed out increased risk in diabetic and hypertensive patients and smokers. Our inability to confirm this may have been due to reduced statistical power. The contribution of postprocedural anticoagulation has also been previously reported (9, 12, 13, 24) . Our finding that previous peripheral vascular disease did not predict complications is at odds with some studies (11) but in agreement with others (14) .
Approximately 19% and 5.8% of the entire study group had diabetes and previous peripheral vascular disease at baseline, respectively. That these factors did not predict vascular complications may relate to greater caution and attention to detail in these patients among participating investigators and hospitals, which is supported by the lower rate of vascular complications among diabetic patients in this and other reported analyses (7, 11) . However, the relative insensitivity of clinical markers for detection of peripheral vascular disease (25) may have resulted in an underestimation of its prevalence in the study patients.
The similarity in complication rates between coronary angioplasty and directional coronary atherectomy (despite larger sheath size used for atherectomy) was also observed in the study of Popma et al. (12) , although others (11) have reported conflicting results. It does appear that after controlling for other baseline and procedural factors, sheath size (within the 8F to 10F range) itself is not an independent determinant of composite vascular complications. In a recent report (13) , smaller sheaths used for stenting were associated with higher complication rates than larger sheaths used for directional atherectomy. This finding was ascribed to anticoagulation. Our finding that peripheral vascular complications were associated with a twofold increase in total hospital costs resulting from greater resource use across all major cost categories has not been previously described in published reports.
Prevention and treatment. The trend for directional coronary atherectomy to be associated with a higher incidence of pulse loss is a reminder that we need to be sensitive to the effects of putting large catheters into small vessels. This trend is reinforced by previously reported vascular complication rates from large mechanical support devices (26) . Although not statistically significant, the trends toward higher overall transfusion rates and greater reduction in hematocrit among patients randomized to directional coronary atherectomy also emphasize the need for more attentiveness to blood loss during these procedures. We have no data to explain the lower frequency of pseudoaneurysms in patients randomized to directional coronary atherectomy; however, it may reflect better attention to insertion technique because operators were aware of the sheath size (27) . This observation should be interpreted cautiously, however, because CAVEAT-I was not prospectively designed to evaluate these complications. The possibility of physician-specific bias in the frequency of obtaining imaging studies in response to clinical suspicion cannot be excluded (9, 28, 29) .
The impact of anticoagulation on vascular complications identifies an area of decision making potentially amenable to modification. In a recent study from the Cleveland Clinic (14) , for example, only 50% of the patients maintained on hepa-rin after intervention had an established indication. The CAVEAT-I experience suggests that indications for continuing heparin after intervention need to be clarified, and algorithms for optimal anticoagulation in relevant circumstances need to be developed. Subcutaneous rather than intravenous administration of heparin may reduce the incidence of hematomas (30) . Attention to proper techniques of early sheath removal guided by activated clotting time has been observed to reduce risks in some studies (31) . Indeed, in our study there was a trend toward longer duration of sheath placement among patients with a vascular complication. Cautious patient mobilization has been advocated by others (32) .
If postprocedural anticoagulation is anticipated, one approach is to extend compression longer than with routine cases; C-clamp and Femostop devices may be helpful. However, excessive compression can cause thrombosis. Sedatives, stool softeners, antitussives, antiemetics and pressure dressings are helpful adjuncts to proper immobilization. In patients who require repeat catheterization, simple measures, such as using alternate access sites (10), compression bandaging of previously used sites (33) , giving attention to entry technique (34) , selective use of antibiotic prophylaxis and avoidance of blood loss (particularly through the Y-adapter), may be helpful. Vascular plugs could become a useful adjunct in the future (35) .
Clinical implications. Patients with peripheral vascular complications had a significantly increased independent risk of adverse long-term outcomes (Table 10) . Possible explanations include the morbidity and mortality inherent in vascular complications and the therapeutic interventions they trigger (transfusions and vascular surgery). In this scenario, complications appear to beget complications (Table 9) . Alternatively, vascular complications and adverse long-term coronary outcomes may be different manifestations of a common clinical substrate. It is probably simplistic to consider the coronary tree in isolation from other parts of the vascular system. The independent effect of peripheral vascular disease on long-term risk among coronary patients, for example, is well established (38, 39) . The role of coronary events in long-term outcomes of patients with large-vessel peripheral vascular disease has also been reported (38, 39) .
Peripheral vascular complications may at least in part be an indicator of overall patient response to current techniques of percutaneous intervention. The severity of this response may highlight a more diffusely diseased or abnormal vasculaturc than previously classified peripheral vascular disease, pure angiographic stratification of coronary disease and lumen results of intervention encompass. Whatever the explanation, the results of CAVEAT-1 strongly suggest that these complications should be vigorously prevented and affected patients followed up more closely than has hitherto been appreciated by the cardiology community (40). Peripheral vascular complications should be collated as part of operator-and hospital-specific data in the emerging environment of scorecard cardiovascular medicine (41) . Our findings may also have implications for designing future clinical trials.
Study limitations. We used a composite definition of peripheral vascular complications to maximize event capture. The present study was not adequately powered to critically examine differences in more narrowly defined hemorrhagic or thromboembolic vascular complications. There is a possibility that results reported therein may therefore be due to chance. In addition, a number of baseline variables of potential interest were not evaluated because of missing or incomplete data. They include the high density lipoprotein/cholesterol ratio, specific sheath size and duration of heparin treatment. Because CAVEAT-I was not primarily designed to evaluate peripheral vascular complications, intensity of diagnostic workup was not controlled. It has been the experience of others (9), for example, that when duplex ultrasound is performed routinely in patients undergoing coronary intervention, the incidence of documented vascular complications may be higher. The impact that such a policy would have on the relative complication rates of coronary angioplasty and directional coronary atherectomy is uncertain.
Conclusions. There was no significant difference in inhospital peripheral vascular complication rates between atherectomy and angioplasty in CAVEAT-I. Older age, female gender and the use of postinterventional heparin or intraaortic balloon counterpulsation were associated with a higher risk. The occurrence of peripheral vascular complications was associated with doubling of in-hospital costs and a much higher likelihood of death, myocardial infarction and repeat revascularization over 1 year.
